$AGEN
AGENUS INC

2017 Q4 Form 10-K Financial Statement

#000156459018006093 Filed on March 16, 2018

View on sec.gov

Income Statement

Concept 2017 Q4 2017 Q3 2017 Q2
Revenue $8.354M $3.359M $4.208M
YoY Change 49.82% -24.45% -36.17%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $9.780M $8.050M $8.140M
YoY Change 12.8% -0.74% 14.33%
% of Gross Profit
Research & Development $31.87M $25.79M $25.82M
YoY Change 22.67% 19.45% 15.47%
% of Gross Profit
Depreciation & Amortization $1.450M $1.500M $1.530M
YoY Change 12.4% 31.58% 19.53%
% of Gross Profit
Operating Expenses $38.35M $35.02M $33.10M
YoY Change 51.88% -13.89% 9.6%
Operating Profit
YoY Change
Interest Expense -$5.100M -$4.700M -$4.475M
YoY Change 11.6% 6.58% 6.54%
% of Operating Profit
Other Income/Expense, Net $60.00K -$470.0K $1.650M
YoY Change -103.19% 235.71% -423.49%
Pretax Income -$35.03M -$36.84M -$31.71M
YoY Change 34.11% -9.64% 11.97%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$35.04M -$36.84M -$31.71M
YoY Change 34.12% -9.64% 11.98%
Net Earnings / Revenue -419.38% -1096.81% -753.64%
Basic Earnings Per Share
Diluted Earnings Per Share -$346.9K -$368.8K -$319.7K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q4 2017 Q3 2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $60.20M $70.10M $96.80M
YoY Change -21.2% -26.52% -21.49%
Cash & Equivalents $60.19M $65.08M $81.83M
Short-Term Investments $0.00 $5.000M $14.90M
Other Short-Term Assets $1.082M $12.00M $9.900M
YoY Change -68.18% 224.32% 200.0%
Inventory $79.49K $100.0K $100.0K
Prepaid Expenses $11.07M
Receivables $1.134M $2.200M $3.900M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $73.55M $84.30M $110.7M
YoY Change -19.44% -23.01% -18.66%
LONG-TERM ASSETS
Property, Plant & Equipment $26.18M $25.60M $25.60M
YoY Change 2.26% 8.94% 40.66%
Goodwill $23.05M
YoY Change
Intangibles $14.41M
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.214M $1.300M $1.300M
YoY Change -6.59% -7.14% -7.14%
Total Long-Term Assets $64.85M $65.00M $65.80M
YoY Change -1.3% -0.46% 8.94%
TOTAL ASSETS
Total Short-Term Assets $73.55M $84.30M $110.7M
Total Long-Term Assets $64.85M $65.00M $65.80M
Total Assets $138.4M $149.3M $176.5M
YoY Change -11.85% -14.59% -10.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.087M $6.700M $4.600M
YoY Change 49.76% 103.03% -8.0%
Accrued Expenses $21.57M $20.60M $20.60M
YoY Change -22.69% -4.19% 5.1%
Deferred Revenue $4.485M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $20.64M $20.00M $100.0K
YoY Change 20539.74% 19900.0% 0.0%
Total Short-Term Liabilities $56.44M $54.40M $32.90M
YoY Change 37.99% 56.32% -0.6%
LONG-TERM LIABILITIES
Long-Term Debt $142.4M $123.3M $138.5M
YoY Change 9.11% -2.38% 13.43%
Other Long-Term Liabilities $3.273M $23.20M $22.50M
YoY Change -31.99% -33.33% -7.79%
Total Long-Term Liabilities $145.7M $146.5M $161.0M
YoY Change 2926.45% -9.06% 9.9%
TOTAL LIABILITIES
Total Short-Term Liabilities $56.44M $54.40M $32.90M
Total Long-Term Liabilities $145.7M $146.5M $161.0M
Total Liabilities $202.1M $200.9M $194.0M
YoY Change 3.06% 2.55% 8.02%
SHAREHOLDERS EQUITY
Retained Earnings -$1.026B
YoY Change 13.38%
Common Stock $1.017M
YoY Change 15.85%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$75.82M -$51.60M -$17.50M
YoY Change
Total Liabilities & Shareholders Equity $138.4M $149.3M $176.5M
YoY Change -11.84% -14.59% -10.18%

Cashflow Statement

Concept 2017 Q4 2017 Q3 2017 Q2
OPERATING ACTIVITIES
Net Income -$35.04M -$36.84M -$31.71M
YoY Change 34.12% -9.64% 11.98%
Depreciation, Depletion And Amortization $1.450M $1.500M $1.530M
YoY Change 12.4% 31.58% 19.53%
Cash From Operating Activities -$25.87M -$26.15M -$27.38M
YoY Change 60.48% 9.78% 48.08%
INVESTING ACTIVITIES
Capital Expenditures -$750.0K -$960.0K -$990.0K
YoY Change -82.68% -80.91% -38.89%
Acquisitions
YoY Change
Other Investing Activities $5.000M $10.00M -$4.970M
YoY Change -66.67% -66.69% -124.83%
Cash From Investing Activities $4.240M $9.040M -$5.960M
YoY Change -60.3% -63.81% -132.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 16.77M 410.0K 1.290M
YoY Change 665.75% -28.07% -127.68%
NET CHANGE
Cash From Operating Activities -25.87M -26.15M -27.38M
Cash From Investing Activities 4.240M 9.040M -5.960M
Cash From Financing Activities 16.77M 410.0K 1.290M
Net Change In Cash -4.860M -16.70M -32.05M
YoY Change 49.54% -1065.32% 574.74%
FREE CASH FLOW
Cash From Operating Activities -$25.87M -$26.15M -$27.38M
Capital Expenditures -$750.0K -$960.0K -$990.0K
Free Cash Flow -$25.12M -$25.19M -$26.39M
YoY Change 113.06% 34.06% 56.43%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
4373000
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3273387
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
1017061
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
951811958
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2169354
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1026475773
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-75815792
CY2017Q4 us-gaap Inventory Net
InventoryNet
79491
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1134493
CY2017Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
11070960
CY2017Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1081993
CY2017Q4 us-gaap Assets Current
AssetsCurrent
73553554
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10924122
CY2016 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2167070
CY2016 agen Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan
StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
1165641
CY2016 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
18275940
CY2015 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
9565639
CY2017 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
2329168
CY2016 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
2155364
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
240000000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
156985986
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
34029085
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
31243967
CY2017Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
5461834
CY2016Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3193092
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
101706117
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
138402024
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2373000
CY2016Q4 agen Accrued Contract Manufacturing Costs
AccruedContractManufacturingCosts
10492000
CY2016Q4 agen Accrued Research Services Current
AccruedResearchServicesCurrent
5639000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1567000
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
33741183
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
116125299
CY2017 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
205541
CY2016 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
204246
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
26178622
CY2017Q4 us-gaap Goodwill
Goodwill
23048804
CY2017Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
14406650
CY2015 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
245183
CY2015 agen Comprehensive Income Loss Available To Common Stockholders Basic
ComprehensiveIncomeLossAvailableToCommonStockholdersBasic
-88166804
CY2015 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
202960
CY2016 agen Vesting Of Nonvested Shares Value
VestingOfNonvestedSharesValue
-768236
CY2016 agen Issuance Of Shares Related To Milestone Achievement Value
IssuanceOfSharesRelatedToMilestoneAchievementValue
886798
CY2017 us-gaap New Accounting Pronouncement Or Change In Accounting Principle Effect Of Adoption Quantification
NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification
-81314
CY2017 agen Stock Issued Under Stock Purchase Agreement Value
StockIssuedUnderStockPurchaseAgreementValue
60000000
CY2017 agen Reclassification Of Liability Classified Option Grants
ReclassificationOfLiabilityClassifiedOptionGrants
-2015974
CY2017 agen Vesting Of Nonvested Shares Value
VestingOfNonvestedSharesValue
-527223
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5559706
CY2017 agen Issuance Of Shares Related To Milestone Achievement Value
IssuanceOfSharesRelatedToMilestoneAchievementValue
1485937
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1214394
CY2017Q4 us-gaap Assets
Assets
138402024
CY2017Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
20639735
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
4484882
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8086992
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21569449
CY2017Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1657063
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
56438121
CY2017Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
142385024
CY2017Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
7748284
CY2016Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
7561000
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4812846
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
877949
CY2016Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
866854348
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1529559
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-905329320
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
-39126266
CY2017 us-gaap Revenue From Grants
RevenueFromGrants
168051
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
23018387
CY2015 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
74669980
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8098650
CY2015 agen Reclassification Of Liability Classified Option Grants
ReclassificationOfLiabilityClassifiedOptionGrants
495742
CY2015 agen Stock Issued Under Stock Purchase Agreement Value
StockIssuedUnderStockPurchaseAgreementValue
35000001
CY2015 agen Issuance Of Shares Related To Milestone Achievement Value
IssuanceOfSharesRelatedToMilestoneAchievementValue
344541
CY2015 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
3038438
CY2015 agen Issuance Of Stock For Settlement Of Contingent Royalty Obligation Value
IssuanceOfStockForSettlementOfContingentRoyaltyObligationValue
2142000
CY2015 agen Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan
StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
1975139
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
70727550
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13323616
CY2016 agen Reclassification Of Liability Classified Option Grants
ReclassificationOfLiabilityClassifiedOptionGrants
318677
CY2016 agen Comprehensive Income Loss Available To Common Stockholders Basic
ComprehensiveIncomeLossAvailableToCommonStockholdersBasic
-126675837
CY2017 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
3188000
CY2016 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
523584
CY2017 agen Comprehensive Income Loss Available To Common Stockholders Basic
ComprehensiveIncomeLossAvailableToCommonStockholdersBasic
-121537828
CY2017 agen Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan
StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
986486
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
16209000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
8249000
CY2017 us-gaap Depreciation And Amortization
DepreciationAndAmortization
6006299
CY2016 us-gaap Depreciation And Amortization
DepreciationAndAmortization
4947787
CY2015 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1957591
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
12428655
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
13188364
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
7438308
CY2017 agen Non Cash Interest Expense
NonCashInterestExpense
18242299
CY2016 agen Non Cash Interest Expense
NonCashInterestExpense
16530437
CY2015 agen Non Cash Interest Expense
NonCashInterestExpense
5626918
CY2017 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-23558
CY2016 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-14733
CY2017 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-3188000
CY2016 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
1953000
CY2015 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
13567000
CY2017 agen Gain On Issuance Of Stock For Settlement Of Milestone Obligation
GainOnIssuanceOfStockForSettlementOfMilestoneObligation
566488
CY2015 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
12245231
CY2015 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-154117
CY2015 us-gaap Business Combination Bargain Purchase Gain Recognized Amount
BusinessCombinationBargainPurchaseGainRecognizedAmount
1522377
CY2015 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-5387067
CY2017 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-10217529
CY2016 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1549798
CY2015 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
9331622
CY2017 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-8709
CY2015 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-7500
CY2017 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
8453082
CY2016 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
650824
CY2015 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
703424
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1647430
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
419708
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2668064
CY2017 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-2722020
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-3939619
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
15957820
CY2017 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-4848372
CY2015 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
11538019
CY2017 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-94225143
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-79960811
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-47175441
CY2015 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
7182069
CY2017 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
120000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3120357
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
12519738
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3591335
CY2017 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
14936047
CY2016 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
54884101
CY2015 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
34993100
CY2017 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
20000000
CY2016 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
85000000
CY2015 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
14534486
CY2017 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
2063596
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
17596161
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-31232018
CY2017 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
65559706
CY2016 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
2167070
CY2015 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
109669980
CY2017 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
986486
CY2016 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1183598
CY2015 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1975139
CY2017 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
527223
CY2016 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
667050
CY2017 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
15000000
CY2015 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
109000000
CY2017 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
150000
CY2015 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
1774323
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.65
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.017
CY2015 us-gaap Repayments Of Debt
RepaymentsOfDebt
1111111
CY2015 agen Payments Of Contingent Purchase Price Consideration
PaymentsOfContingentPurchasePriceConsideration
8180000
CY2016 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
5000000
CY2015 agen Payment Of Contingent Royalty Obligation
PaymentOfContingentRoyaltyObligation
20000000
CY2017 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
330744
CY2016 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
144658
CY2017 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
80538225
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-2461040
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
189579685
CY2017 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
361923
CY2016 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-429167
CY2015 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-183873
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-11261399
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-65254857
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
110988354
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
136702873
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25714519
CY2017 us-gaap Interest Paid
InterestPaid
1120000
CY2016 us-gaap Interest Paid
InterestPaid
1120000
CY2015 us-gaap Interest Paid
InterestPaid
1053447
CY2017 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
968400
CY2016 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
695466
CY2015 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
105245
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.97
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
132000
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
3800000
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12429000
CY2015 agen Clinical Trials Expense
ClinicalTrialsExpense
19900000
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;text-indent:2.27%;">(c) Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. We base those estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances. Actual results could differ from those estimates.</p></div>
CY2017Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
60200000
CY2017 agen Increase Decrease In Cash Cash Equivalents And Short Term Investments
IncreaseDecreaseInCashCashEquivalentsAndShortTermInvestments
-16300000
CY2017Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
123800000
CY2017Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
96800000
CY2017Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
70100000
CY2018Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
86800000
CY2017Q1 agen Increase Decrease In Cash Cash Equivalents And Short Term Investments
IncreaseDecreaseInCashCashEquivalentsAndShortTermInvestments
47400000
CY2017Q2 agen Increase Decrease In Cash Cash Equivalents And Short Term Investments
IncreaseDecreaseInCashCashEquivalentsAndShortTermInvestments
-27000000
CY2017Q3 agen Increase Decrease In Cash Cash Equivalents And Short Term Investments
IncreaseDecreaseInCashCashEquivalentsAndShortTermInvestments
-26700000
CY2017Q4 agen Increase Decrease In Cash Cash Equivalents And Short Term Investments
IncreaseDecreaseInCashCashEquivalentsAndShortTermInvestments
-9900000
CY2018Q1 agen Increase Decrease In Cash Cash Equivalents And Short Term Investments
IncreaseDecreaseInCashCashEquivalentsAndShortTermInvestments
26600000
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-14800000
CY2017Q2 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-27400000
CY2017Q3 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-26200000
CY2017Q4 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-25800000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-17103000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-31713000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-36842000
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-35035000
CY2017 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2017Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2016Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2017 us-gaap Depreciation
Depreciation
3800000
CY2016 us-gaap Depreciation
Depreciation
2700000
CY2015 us-gaap Depreciation
Depreciation
1400000
CY2017Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
129146000
CY2016Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
114146000
CY2017 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
1900000
CY2016 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-2100000
CY2015 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-866000
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2017 agen Transition Tax
TransitionTax
0
CY2017 agen Tax Cuts And Jobs Act Of2017 Not Yet Effective Current Deductibility Of Net Interest Expense In Excess Of Limitation Percentage Of Taxable Income
TaxCutsAndJobsActOf2017NotYetEffectiveCurrentDeductibilityOfNetInterestExpenseInExcessOfLimitationPercentageOfTaxableIncome
0.30
CY2017 agen Tax Cuts And Jobs Act Of2017 Not Yet Effective Net Operating Loss Limitation Percentage Of Taxable Income
TaxCutsAndJobsActOf2017NotYetEffectiveNetOperatingLossLimitationPercentageOfTaxableIncome
0.80
CY2017 agen Tax Cuts And Jobs Act Of2017 Not Yet Effective Minimum Tax On Certain Foreign Earnings In Excess Of Foreign Subsidiaries Tangible Assets
TaxCutsAndJobsActOf2017NotYetEffectiveMinimumTaxOnCertainForeignEarningsInExcessOfForeignSubsidiariesTangibleAssets
0.10
CY2017 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2017Q4 agen Common Stock Closing Price Per Share
CommonStockClosingPricePerShare
3.55
CY2017 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
657000
CY2017 us-gaap Indefinitelived Intangible Assets Acquired
IndefinitelivedIntangibleAssetsAcquired
1928000
CY2017Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
19869000
CY2016 us-gaap Indefinitelived Intangible Assets Acquired
IndefinitelivedIntangibleAssetsAcquired
1846000
CY2016Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
19558000
CY2017 us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P9Y
CY2017 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2300000
CY2016 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2200000
CY2015 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
525000
CY2017Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
2000000
CY2017Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1900000
CY2017Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1900000
CY2017Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1900000
CY2017Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
1900000
CY2017 agen Available For Sale Securities Sold Before Maturity
AvailableForSaleSecuritiesSoldBeforeMaturity
0
CY2017Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
57000000
CY2016Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
48900000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
60208000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
56878000
CY2017Q4 agen Deferred Tax Assets Operating Loss Carry Forwards Federal And State
DeferredTaxAssetsOperatingLossCarryForwardsFederalAndState
185535000
CY2016Q4 agen Deferred Tax Assets Operating Loss Carry Forwards Federal And State
DeferredTaxAssetsOperatingLossCarryForwardsFederalAndState
241572000
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
13075000
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
19597000
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
17723000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
13165000
CY2016Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
15513000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
235811000
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
301048000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
232443000
CY2017Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
6221000
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
295502000
CY2017Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
3368000
CY2016Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
5546000
CY2017Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
3960000
CY2016Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
6197000
CY2017Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
592000
CY2016Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
651000
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-41035000
CY2016 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-42781000
CY2015 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-31669000
CY2017 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-63868000
CY2016 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
35471000
CY2015 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
25908000
CY2016 us-gaap Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
-203000
CY2015 us-gaap Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
203000
CY2017 us-gaap Income Tax Reconciliation Tax Contingencies State And Local
IncomeTaxReconciliationTaxContingenciesStateAndLocal
-4561000
CY2016 us-gaap Income Tax Reconciliation Tax Contingencies State And Local
IncomeTaxReconciliationTaxContingenciesStateAndLocal
-3452000
CY2015 us-gaap Income Tax Reconciliation Tax Contingencies State And Local
IncomeTaxReconciliationTaxContingenciesStateAndLocal
-3869000
CY2017 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
104764000
CY2017 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
2084000
CY2016 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
4398000
CY2015 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-314000
CY2017 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
2616000
CY2016 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
6567000
CY2015 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
4354000
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
5278000
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
5481000
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
5778000
CY2015 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
203000
CY2016 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
203000
CY2015 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
500000
CY2017 agen Unrecognized Tax Benefits Decreases Resulting From Change In Federal Tax Rate
UnrecognizedTaxBenefitsDecreasesResultingFromChangeInFederalTaxRate
929000
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
4349000
CY2017Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
7790000
CY2016Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
6504000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2021000
CY2017Q4 agen Accrued Contract Manufacturing Costs
AccruedContractManufacturingCosts
5528000
CY2017Q4 agen Accrued Research Services Current
AccruedResearchServicesCurrent
4663000
CY2016Q4 agen Accrued Leasehold Improvements Current
AccruedLeaseholdImprovementsCurrent
1280000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1587000
CY2016Q4 agen Current Portion Purchase Price
CurrentPortionPurchasePrice
3948000
CY2017Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
1657000
CY2016Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
843000
CY2016Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
140000000
CY2008Q1 agen Shares Issued In Private Placements Shares
SharesIssuedInPrivatePlacementsShares
1451450
CY2008Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
18.00
CY2008Q1 agen Class Of Warrant Or Right Term
ClassOfWarrantOrRightTerm
P10Y
CY2008Q1 agen Class Of Warrant Or Right Exercisable Term
ClassOfWarrantOrRightExercisableTerm
P9Y6M
CY2008Q1 agen Warrants Issued
WarrantsIssued
1451450
CY2017 agen Shares Issued For Contingent Milestone Payment
SharesIssuedForContingentMilestonePayment
80493
CY2017 agen Shares Issued For Contingent Milestone Payment Value
SharesIssuedForContingentMilestonePaymentValue
345000
CY2015Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
12650000
CY2015Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
75000000
CY2017Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
530864
CY2017Q4 agen Weighted Average Stock Price Of Shares Credited Under Director Deferred Compensation Plan
WeightedAverageStockPriceOfSharesCreditedUnderDirectorDeferredCompensationPlan
5.24
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.65
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.77
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.010
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.016
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11693400
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4499342
CY2017 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
160325
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1164758
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
500872
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
14366787
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
14366787
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
8164576
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.51
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.81
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.47
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.29
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
7.42
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.22
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
4.22
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
4.37
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M26D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y2M26D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y10D
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
707661
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
707661
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
699061
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.65
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
445000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1200000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1942476
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
711300
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
1097243
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
242983
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1313550
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
6.45
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.84
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
7.75
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
6.21
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
2.91
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
2400000
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
140000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
570037
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
35332
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13188000
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7438000
CY2017Q4 agen Estimate Of Payments For Clinical Trials
EstimateOfPaymentsForClinicalTrials
182100000
CY2017 agen Clinical Trials Expense
ClinicalTrialsExpense
35800000
CY2016 agen Clinical Trials Expense
ClinicalTrialsExpense
23100000
CY2017Q4 agen Cumulative Payments For Clinical Trials
CumulativePaymentsForClinicalTrials
124100000
CY2014Q1 us-gaap Stock Issued During Period Shares Acquisitions
StockIssuedDuringPeriodSharesAcquisitions
996088
CY2014Q1 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
3000000
CY2015Q1 us-gaap Business Combination Contingent Consideration Arrangements Range Of Outcomes Value High
BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
6200000
CY2017 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
2600000
CY2016 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
3300000
CY2015 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
2300000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
3179000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
2445000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
2273000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
1902000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
1944000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
2469000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
14212000
CY2017Q4 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
1000000
CY2017 agen Amounts Drawn On Letter Of Credit
AmountsDrawnOnLetterOfCredit
0
CY2017Q4 us-gaap Security Deposit
SecurityDeposit
200000
CY2017 us-gaap Rental Income Nonoperating
RentalIncomeNonoperating
562000
CY2016 us-gaap Rental Income Nonoperating
RentalIncomeNonoperating
733000
CY2015 us-gaap Rental Income Nonoperating
RentalIncomeNonoperating
780000
CY2017Q4 us-gaap Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
288000
CY2017Q4 us-gaap Capital Leases Future Minimum Payments Due In Three Years
CapitalLeasesFutureMinimumPaymentsDueInThreeYears
288000
CY2017Q4 us-gaap Capital Leases Future Minimum Payments Due In Four Years
CapitalLeasesFutureMinimumPaymentsDueInFourYears
144000
CY2017Q4 agen Long Term Debt Current Principal Amount
LongTermDebtCurrentPrincipalAmount
15146000
CY2017 agen Long Term Debt Current Interest Expense
LongTermDebtCurrentInterestExpense
5494000
CY2017Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
20640000
CY2017Q4 agen Long Term Debt Noncurrent Principal Amount
LongTermDebtNoncurrentPrincipalAmount
114000000
CY2016Q4 agen Long Term Debt Noncurrent Principal Amount
LongTermDebtNoncurrentPrincipalAmount
114000000
CY2017 us-gaap Interest Expense Debt
InterestExpenseDebt
31323000
CY2016 us-gaap Interest Expense Debt
InterestExpenseDebt
19421000
CY2017Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
1362000
CY2016Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
1345000
CY2017Q4 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
1576000
CY2016Q4 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
1533000
CY2017Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
142385000
CY2016Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
130542000
CY2017 agen Interest Expense Debt Non Operating
InterestExpenseDebtNonOperating
36816000
CY2016 agen Interest Expense Debt Non Operating
InterestExpenseDebtNonOperating
19421000
CY2017Q4 agen Unamortized Debt Issuance Expense Long Term
UnamortizedDebtIssuanceExpenseLongTerm
1362000
CY2016Q4 agen Unamortized Debt Issuance Expense Long Term
UnamortizedDebtIssuanceExpenseLongTerm
1345000
CY2017Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1576000
CY2016Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1533000
CY2017Q4 us-gaap Long Term Debt And Capital Lease Obligations Including Current Maturities
LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
163025000
CY2016Q4 us-gaap Long Term Debt And Capital Lease Obligations Including Current Maturities
LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
130688000
CY2015Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
3000000
CY2015Q1 us-gaap Debt Instrument Convertible Remaining Discount Amortization Period1
DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
P3Y
CY2017Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
0
CY2017Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
0
CY2017Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
0
CY2017Q4 agen Contingent Consideration Liability Fair Value Disclosure
ContingentConsiderationLiabilityFairValueDisclosure
4373000
CY2017Q4 us-gaap Nonfinancial Liabilities Fair Value Disclosure
NonfinancialLiabilitiesFairValueDisclosure
4373000
CY2016Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
9990000
CY2016Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
14978000
CY2016Q4 agen Contingent Consideration Liability Fair Value Disclosure
ContingentConsiderationLiabilityFairValueDisclosure
7561000
CY2017Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2017 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
487000
CY2016 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
334000
CY2015 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
307000
CY2017 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
487000
CY2016 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
334000
CY2015 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
307000
CY2017Q4 us-gaap Noncurrent Assets
NoncurrentAssets
27393000
CY2016Q4 us-gaap Noncurrent Assets
NoncurrentAssets
26917000
CY2017Q1 us-gaap Revenues
Revenues
26956000
CY2017Q2 us-gaap Revenues
Revenues
4208000
CY2017Q3 us-gaap Revenues
Revenues
3359000
CY2017Q4 us-gaap Revenues
Revenues
8354000
CY2017Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17154000
CY2017Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-31764000
CY2017Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-36893000
CY2017Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-35087000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.18
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.32
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
CY2017Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.35
CY2016Q1 us-gaap Revenues
Revenues
5959000
CY2016Q2 us-gaap Revenues
Revenues
6592000
CY2016Q3 us-gaap Revenues
Revenues
4446000
CY2016Q4 us-gaap Revenues
Revenues
5576000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-31779000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-28320000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-40774000
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-26122000
CY2016Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-31829000
CY2016Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-28371000
CY2016Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-40825000
CY2016Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-26174000
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.33
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.47
CY2016Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.30

Files In Submission

Name View Source Status
0001564590-18-006093-index-headers.html Edgar Link pending
0001564590-18-006093-index.html Edgar Link pending
0001564590-18-006093.txt Edgar Link pending
0001564590-18-006093-xbrl.zip Edgar Link pending
agen-10k_20171231.htm Edgar Link pending
agen-20171231.xml Edgar Link completed
agen-20171231.xsd Edgar Link pending
agen-20171231_cal.xml Edgar Link unprocessable
agen-20171231_def.xml Edgar Link unprocessable
agen-20171231_lab.xml Edgar Link unprocessable
agen-20171231_pre.xml Edgar Link unprocessable
agen-ex211_12.htm Edgar Link pending
agen-ex231_7.htm Edgar Link pending
agen-ex311_9.htm Edgar Link pending
agen-ex312_6.htm Edgar Link pending
agen-ex321_8.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g2018031620520368415796.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R88.htm Edgar Link pending
R89.htm Edgar Link pending
R9.htm Edgar Link pending
R90.htm Edgar Link pending
R91.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending